Fushine(SZ:300497) Shang Hai Zheng Quan Bao·2025-08-26 20:06Core Viewpoint - The company has made significant progress in its strategic development, focusing on optimizing governance structures and enhancing operational efficiency while achieving a reduction in net losses during the first half of 2025 [5][6]. Company Overview - The company reported a revenue of 514.67 million yuan in the first half of 2025, with a net profit attributable to shareholders of -6.91 million yuan, reflecting a year-on-year reduction in losses by 15.55 million yuan [5][6]. Key Developments - The company has optimized its governance structure, ensuring continuity and stability through the re-election of the board and the appointment of senior management [6]. - The company’s new protein product successfully obtained GRAS certification in the U.S., facilitating its entry into international markets [6]. - The company was included in the first batch of the national bio-manufacturing landmark product list, showcasing its technological strength in the field of microbial protein [6]. Future Plans - For the second half of 2025, the company will focus on three main business divisions: pharmaceuticals, new energy, and synthetic biology, aiming to enhance marketing and R&D capabilities [7]. - The pharmaceutical division plans to deepen collaboration with key customers and enhance product development to improve market competitiveness [8]. - The new energy division aims to strengthen strategic partnerships and optimize production processes to reduce costs and enhance operational efficiency [8]. - The synthetic biology division will focus on commercializing its new protein product and expanding its market presence through innovative applications [9][10]. Product Development - The company is advancing its amino acid water-soluble fertilizer product, which utilizes by-products from its new protein production process, aiming for certification and market launch in the second half of 2025 [12].